Panelists discuss how emerging therapies like menin inhibitors show promise based on strong preclinical data and clinical responses, while CD47 inhibitors have faced setbacks in phase 3 trials, with ...
Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs ...
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback